Renal Cell Carcinoma
Renal Cell Carcinoma
Zachary BessetteAdvanced Renal Cell Carcinoma | December 6, 2022
For patients with mRCC, durable complete response to sunitinib can be achieved irrespective of prognostic group...
Read More
Emily MenendezAdvanced Renal Cell Carcinoma | December 6, 2022
Patients with mccRCC and high body mass index may experience better outcomes when treated with immune checkpoint blockades.
Leah LawrenceRenal Cell Carcinoma | November 28, 2022
Patients who had single-fraction SABR had better performance status and less local failures compared with multifraction SABR.
Leah LawrenceRenal Cell Carcinoma | November 28, 2022
An association between PET avidity and histologic grading suggested that positive scans resulted in more aggressive disease.
Akhil Abraham Saji, MDJournal | November 22, 2022
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
David Ambinder, MDJournal | November 22, 2022
Robert Uzzo gives an overview of the RENAL score that he developed, plus his outlook on the future of renal characterization.
The UromigosUromigos Live and Unplugged | November 4, 2022
Sumanta Pal, MD, FASCO, from City of Hope talks about new drugs and the ongoing TiNivo-2 trial for renal cell carcinoma.
The UromigosUromigos Live and Unplugged | November 4, 2022
David McDermott, MD talks about monotherapy and combination therapy for RCC and future advances in RCC treatment.
David Ambinder, MDJournal | October 24, 2022
A review of “A Comparison of Percutaneous Ablation Therapy to Partial Nephrectomy for cT1a Renal Cancers” from the CKCis.
Daniel Tennenbaum, MDJournal | October 24, 2022
A guide to hereditary RCCs and their syndromes, as well as the relevant recommended guidelines for diagnosis and management.
Akhil Abraham Saji, MDJournal | October 24, 2022
Integrated imaging with PET/CT has allowed clinicians to gain significant anatomical and oncologic information on tumors.
Leah LawrenceRenal Cell Carcinoma | October 18, 2022
MIS had lower 1-year postdischarge readmission rate and less outpatient visits for partial and radical nephrectomy.
Leah LawrenceLocalized Renal Cell Carcinoma | October 18, 2022
Checkmate 914 assigned patients to nivolumab plus ipilimumab or placebo and found no difference in disease-free survival.
The UromigosUromigos Live and Unplugged | October 17, 2022
Tian Zhang gives a quick recap of the Frontline Therapy in RCC panel from The Uromigos Live & Unplugged.
The UromigosUromigos Live and Unplugged | October 17, 2022
Axel Bex gives a quick recap of the renal panel on adjuvant therapy in RCC from The Uromigos Live & Unplugged.
The UromigosUromigos Live and Unplugged | October 14, 2022
The Uromigos and a panel of RCC experts discuss data on perioperative therapy in RCC, and the next adjuvant therapy trials.
The UromigosUromigos Live and Unplugged | October 14, 2022
A panel of RCC experts discuss frontline therapy for kidney cancer, as well as where they see it headed in the next 5 years.
Akhil Abraham Saji, MDJournal | September 27, 2022
Socioeconomic disadvantages, disparities, and equitable access in kidney and bladder cancer care are reviewed.
David Ambinder, MDJournal | September 27, 2022
According to a recent study, laparoscopic surgery may be equivalent to open surgery for performing partial nephrectomies.
Daniel Tennenbaum, MDJournal | September 27, 2022
Limited evidence of the feasibility of robot-assisted laparoscopic radical nephrectomy with IVC thrombectomy exists.
Advertisement
Advertisement